Mayne Pharma (ASX:MYX), Nyrada (ASX:NYR) and Nine Entertainment (ASX:NEC): Three Companies Reporting Fresh Updates

Sonal Goyal

06 November 2026 09:25 PM AEDT

Mayne Pharma (ASX:MYX), Nyrada (ASX:NYR) and Nine Entertainment (ASX:NEC): Three Companies Reporting Fresh Updates

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Mayne Pharma (ASX:MYX) finished the 6 November 2026 session at $3.08, up 13.65%, on the day it announced a $55.5 million sale of its international segment.
Nine Entertainment (ASX:NEC) finished at $0.815, up 11.64%, alongside its AGM trading update of the same date.
Nyrada (ASX:NYR) finished at $0.495, up 11.24%, with its most recent update dated 19 October 2026.

During the Trading session on 6 November 2026, Mayne Pharma Group Limited (ASX:MYX) finished at $3.08, up 13.65%, Nyrada Inc (ASX:NYR) finished at $0.495, up 11.24%, and Nine Entertainment Co. Holdings Limited (ASX:NEC) finished at $0.815, up 11.64%. The S&P/ASX 200 fell 0.49% to 9,020.80 over the same session. The three companies span specialty pharmaceuticals, clinical-stage biotechnology and media.

Mayne Pharma Group Limited (ASX:MYX)

On 6 November 2026, Mayne Pharma announced a binding agreement to sell Mayne Pharma International for $55.5 million in cash to an entity owned by General Pharma Bidco, the vehicle for Evaris Pharma. Completion is expected in the third quarter of FY27, subject to ACCC approval.

The company said the sale completes its transition to a specialty pharmaceutical Business focused 100% on the United States.

Nyrada Inc (ASX:NYR)

In its Quarterly Report dated 19 October 2026, Nyrada reported four hospitals activated in the PROTECT-MI Phase IIa trial, with cash of $13.72 million at 30 September 2026 and FDA pre-IND feedback raising no major issues.

Nyrada is a clinical-stage biotechnology company developing TRPC ion channel inhibitors, led by Xolatryp.

Nine Entertainment Co. Holdings Limited (ASX:NEC)

In its AGM trading update of 6 November 2026, Nine said it expects another year of Revenue and EBITDA growth in FY27 on a pro forma FY26 basis, with EBITDA weighted to the second half. Nine Publishing digital subscription revenue rose 7% in the first quarter.

Nine operates television, publishing, the Stan streaming service and outdoor advertising.

Sector Context

Pharmaceutical portfolios are often reshaped through divestments, while clinical-stage biotechnology depends on trial enrolment and funding. Australian media companies are adjusting to changing Advertising patterns and digital platform regulation, including news bargaining rules.

Risks to Watch

Mayne Pharma's sale requires ACCC approval and includes Working Capital adjustments. Nyrada's trial timetable depends on site activation and funding. Nine's FY27 growth expectations rely on the second half and on economic conditions that the company itself describes as uncertain.

Catalysts on Watch

Investors will be watching for ACCC clearance and completion of the Mayne sale, Nyrada's site activations by the end of November 2026, and Nine's News Bargaining Incentive timing during FY27.

FAQs

Q: What is Mayne Pharma selling?

A: It is selling Mayne Pharma International Pty Ltd for $55.5 million in cash.

Q: When is the Mayne sale expected to complete?

A: Completion is expected in the third quarter of FY27, subject to ACCC approval.

Q: How many hospitals are active in Nyrada's trial?

A: Four hospitals were activated at the time of its October 2026 report.

Q: What does Nine expect for FY27?

A: Another year of revenue and EBITDA growth on a pro forma FY26 basis, weighted to the second half.

Q: How did the three shares move on 6 November 2026?

A: Mayne Pharma rose 13.65% to $3.08, Nyrada rose 11.24% to $0.495 and Nine rose 11.64% to $0.815, while the S&P/ASX 200 fell 0.49%.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.